News and events for Arizona’s Biotech Community
|
Author Archive: AZBio
New Online Tool Helps Patients with Actionable Cost Information on Their Medicines
A new platform for patients, caregivers and health care providers called the Medicine Assistance Tool, or MAT is a tool that links to the websites referenced in company Direct to Consumer (DTC) television advertising and includes a search tool to help patients connect to financial assistance programs.
Banner Alzheimer’s Institute to build memory and research center in Tucson
The multidisciplinary center will operate in partnership with University of Arizona.Continue reading
Private Equity Firm Purchases Phoenix-based Regenerative Medicine Company Axolotl Biologix
Company Plans to Initiate Clinical Trials and FDA Approvals of its ProductsContinue reading
Arizona Commerce Authority Announces Arizona Innovation Challenge Finalists for Spring 2019
The Arizona Commerce Authority (ACA) today announced 25 companies were selected as semifinalists in the Spring 2019 round of the Arizona Innovation Challenge.
UA College of Medicine- Phoenix Graduates its 500th Physician Today
The University of Arizona College of Medicine – Phoenix will graduate its 500th physician Monday, May 6, during commencement ceremonies at the Orpheum Theatre in downtown Phoenix.Continue reading
UA College of Medicine – Phoenix Partners with Space Tango to Test Diagnostic Tool in Space
Center for Applied NanoBioscience and Medicine will Integrate Its Health Platform in the Company’s Automated CubeLab System Continue reading
HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases
Amendment allows for the development of IVD test kits compatible with Illumina technologyContinue reading
FDA Approves Genentech’s Kadcyla for Adjuvant Treatment of People with HER2-Positive Early Breast Cancer with Residual Invasive Disease After Neoadjuvant Treatment
– Approval based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer –
– Application approved under FDA’s Real-Time Oncology Review pilot program –Continue reading